Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of research firms have recently weighed in on AMLX. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Mizuho upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $3.00 to $7.00 in a report on Monday, April 7th.

Amylyx Pharmaceuticals Trading Down 6.5 %

Amylyx Pharmaceuticals stock traded down $0.35 during trading on Friday, hitting $5.01. The company had a trading volume of 547,092 shares, compared to its average volume of 1,248,449. The company's 50 day simple moving average is $3.70 and its 200-day simple moving average is $4.17. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $7.27. The stock has a market cap of $443.90 million, a price-to-earnings ratio of -1.31 and a beta of -0.53.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. As a group, analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Camille L. Bedrosian sold 12,425 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $43,114.75. Following the completion of the sale, the insider now owns 194,375 shares in the company, valued at $674,481.25. The trade was a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total value of $41,122.97. Following the completion of the transaction, the chief executive officer now directly owns 3,201,247 shares of the company's stock, valued at $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,509 shares of company stock worth $222,586. Corporate insiders own 11.70% of the company's stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. XTX Topco Ltd boosted its stake in Amylyx Pharmaceuticals by 12.0% in the fourth quarter. XTX Topco Ltd now owns 53,376 shares of the company's stock valued at $202,000 after acquiring an additional 5,704 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Amylyx Pharmaceuticals by 11.8% during the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company's stock worth $403,000 after purchasing an additional 11,214 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at about $45,000. Institutional investors and hedge funds own 95.84% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.